Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stimcell EnergeticsSTME 26 EV-to-EBITDA is -8.01 as of Jul. 20, 2026. GuruFocus rates STME with a GF Score™ of 26/100. The stock has 4 warning signs investors should review. Among 510 Medical Devices & Instruments companies, Stimcell Energetics ranks worse than 196078.24% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Stimcell Energetics's enterprise value is $6.61 Mil.
Stimcell Energetics's EBITDA for the trailing twelve months (TTM) ended in Feb. 2026 was $-0.83 Mil. Therefore, Stimcell Energetics's EV-to-EBITDA for today is -8.01.
The historical rank and industry rank for Stimcell Energetics's EV-to-EBITDA or its related term are showing as below:
STME'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -63.85 Med: -6.46 Max: -1.99
Current: -8.01
During the past 13 years, the highest EV-to-EBITDA of Stimcell Energetics was -1.99. The lowest was -63.85. And the median was -6.46.
STME's EV-to-EBITDA is ranked worse than 100% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.155
vs STME: -8.01
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Stimcell Energetics's PE Ratio (TTM) for today is calculated as:
Stimcell Energetics's share price for today is $0.276.
Stimcell Energetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Stimcell Energetics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Stimcell Energetics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stimcell Energetics EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stimcell Energetics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Stimcell Energetics's EV-to-EBITDA falls into.
Stimcell Energetics's current Enterprise Value is $6.61 Mil.
Stimcell Energetics's EBITDA for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.83 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stimcell Energetics (STME) has a EV-to-EBITDA of -8.01 as of Jul. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Stimcell Energetics. According to the industry distribution chart, Stimcell Energetics ranks #999999 out of 510 companies in the Medical Devices & Instruments industry.
Is Stimcell Energetics' EV-to-EBITDA too high?
Stimcell Energetics' current EV-to-EBITDA is -8.01. Based on the distribution chart, Stimcell Energetics ranks #999999 out of 510 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Stimcell Energetics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Stimcell Energetics' EV-to-EBITDA compare to NVNO and TRIB?
According to the Medical Devices & Instruments industry distribution chart, Stimcell Energetics ranks #999999 out of 510 companies for EV-to-EBITDA. This places Stimcell Energetics in the lower half of its industry. The industry median EV-to-EBITDA is 14.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.16, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Stimcell Energetics. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stimcell Energetics's current EV-to-EBITDA is -8.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stimcell Energetics stock overvalued right now?
Stimcell Energetics (STME) has a current EV-to-EBITDA of -8.01. The current EV-to-EBITDA is -8.01. Stimcell Energetics' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Stimcell Energetics (STME), the current EV-to-EBITDA is -8.01 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Stimcell Energetics Inc is a biotech company focused on the discovery, development, and commercialization of therapeutic and non-therapeutic products that enhance cellular function, promote general wellness, and alleviate health complications, including, but not limited to: aging, diabetes, high blood pressure, neuropathy, and kidney function. The company's main focus is on continued research and development of its eBalance Technology and its eBalance Home System.
26GF Score
Get the complete analysis for STME
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STME has been successfully added to your 
